Andrew Arno Acquires 33,898 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno acquired 33,898 shares of the stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OncoCyte Stock Performance

OCX stock opened at $2.53 on Tuesday. OncoCyte Co. has a 1-year low of $2.08 and a 1-year high of $6.80. The business has a fifty day moving average price of $2.96 and a 200-day moving average price of $3.06.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new position in shares of OncoCyte in the second quarter worth $25,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of OncoCyte in the first quarter worth $25,000. Renaissance Technologies LLC grew its holdings in shares of OncoCyte by 131.7% in the second quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock worth $32,000 after acquiring an additional 78,500 shares during the period. DCF Advisers LLC grew its holdings in shares of OncoCyte by 107.0% in the first quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock worth $37,000 after acquiring an additional 13,000 shares during the period. Finally, Balyasny Asset Management LLC grew its holdings in shares of OncoCyte by 389.9% in the third quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock worth $39,000 after acquiring an additional 42,091 shares during the period. Hedge funds and other institutional investors own 55.35% of the company’s stock.

Wall Street Analyst Weigh In

OCX has been the subject of a number of recent research reports. StockNews.com initiated coverage on OncoCyte in a research note on Friday. They set a “sell” rating for the company. Benchmark reiterated a “speculative buy” rating and set a $5.00 price objective on shares of OncoCyte in a research note on Monday.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.